Table 1.
Patients’ characteristics.
| Total number of patients | 50 |
| ECOG | |
| Ø | 31(62%)) |
| 1 | 17 (34%) |
| 2 | 2(4%) |
| Median age | 55 (28–86) |
| ≤50 years | 19 (38%) |
| >50 years | 31(62%) |
| Sex | |
| Male | 1/50 (2%) |
| Female | 49/50 (98%) |
| Breast cancer | |
| Number of patients | 44 (88%) |
| Histotype | |
| Luminal | 23 (46%) |
| HER2+ | 18 (36%) |
| Triple negative | 3 (6%) |
| Stages | |
| I–III | 19/44 (38%) |
| IV | 25/44 (50%) |
| Gynecological cancer | |
| Number of patients | 6 (12%) |
| Stages | 2/6 (33%) |
| I–II | 4/6 (77%) |
| IV | |
| Breast cancer patients | |
| Number of patients | 44 (88%) |
| •Early breast cancer setting | 19/44 (38%) |
| Anthracycline-based chemo± target therapy* | 15 |
| Maintenance target therapy without chemo* | 4 |
| • Advanced breast cancer | 25/44 (50%) |
| Chemotherapy ± target therapy* | 9 |
| Target therapy without chemo** | 16 |
| Gynecological tumors | |
| Number of patients | 6/50 (12%) |
| •Early setting | 2/6 (33%) |
| Platinum-based chemotherapy | 2 |
| •Advanced disease | 4/6 (77%) |
| Platinum-based chemo | 2 |
| Target therapy without chemo*** | 2 |
Chemotherapies: single agents platinum (2 pts), eribulin (2 pts), and paclitaxel (5 pts) monochemotherapy.
target therapies: * pertuzumab and trastuzumab or trastuzumab alone; ** pertuzumab plus trastuzumab or trastuzumab alone, TDM1, bevacizumab; *** bevacizumab.
ECOG, Eastern Cooperative Oncology Group.